The National Blood Authority (NBA) is a statutory agency within the Australian Government Health portfolio that manages and coordinates arrangements for the supply of blood and blood products and services on behalf of the Australian Government and state and territory governments.
The NBA was established by the National Blood Authority Act 2003 following the signing of the original National Blood Agreement (see links below) by all state and territory health ministers. The National Blood Agreement sets out the primary and secondary policy objectives of all Australian governments in relation to the Australian blood sector. The Australian Government, and state and territory governments, signed the agreement in 2002 and, in so doing, agreed to implement a coordinated national approach to policy setting, governance and management of the Australian blood sector, including administrative and financial arrangements.
Under the agreement, blood products are provided at no direct cost to patients. The NBA is funded by the Australian Government (63%) and by the states and territories (37%), with the funding provided by each state and territory determined by the quantity of product provided to each particular state and territory.
The National Blood Agreement’s primary policy objectives are:
- to provide an adequate, safe, secure and affordable supply of blood products, blood-related products and blood-related services in Australia; and
- to promote safe, high-quality management and use of blood products, blood-related products and blood-related services in Australia.
A supporting principle is that blood and blood-related products can be accessed by patients at no direct cost, provided such use is in accordance with clinical need and appropriate clinical practice.
- National Blood Agreement - Original (pdf) (2.94 MB)
- Amendment to National Blood Agreement (pdf) (104.17 KB)
- Full Varied National Blood Agreement (pdf) (135.16 KB)
Saving and improving Australian lives through a world-class blood supply.
The NBA represents the interests of the Australian and state and territory governments, and sits within the Australian Government’s Health portfolio.
The key role of the NBA is to:
- provide an adequate, safe, secure and affordable supply of blood products, blood related products and blood related services, and
- promote safe, high quality management and use of blood products, blood related products and blood related services in Australia.
- works with jurisdictions to determine the clinical requirements for blood and blood products to meet national clinical needs and develop an annual supply plan and budget
- negotiates and manages national contracts with suppliers of blood and blood products to obtain the products needed
- assesses blood supply risk and engages in contingency planning for risks arising in the sector and impacting on the sector
- supports the work of the jurisdictions to improve the way blood products are used - including developing and facilitating strategies and programs that will improve the safety, quality and effectiveness of blood usage, particularly in the areas of national standards, guidelines and data capture and analysis
- provides expert advice to support government policy development, including identification of emerging risks, developments, trends and new opportunities
- manages the evaluation of proposals for blood sector improvements, including proposals for new products, technologies and system changes
- provides secretariat support to the Jurisdictional Blood Committee (JBC).
We recognise the important role that blood and blood products play in the treatment and clinical management of Australian patients and are committed to:
- meeting patient needs for the provision of a safe, secure, adequate and affordable supply of blood and blood products
- working collaboratively with stakeholders to develop, monitor and improve national networks and systems for improved clinical awareness and practices in the use of blood and blood products
- developing the professional and technical competence of our staff
- delivering our mission in an efficient, professional, inclusive, responsive and innovative manner.
John Cahill has been the Chief Executive of the National Blood Authority since October 2016.
He was appointed to this position from a senior executive position with the Australian Government Department of Health. He has wide ranging policy, program and operational experience, including extensive work as a senior executive and Chief Executive with various government departments and agencies.
Before coming to the NBA, John led and managed major programs and projects involving the delivery of challenging and complex services across Australia and internationally. This included the management and delivery of significant health services, infrastructure services, major procurement and the management of substantial contracts.
Since commencing with the NBA, John has worked closely with the Australian Red Cross Blood Service, with commercial suppliers and service providers, with a broad range of committed stakeholders within governments and the community, as well as with the passionate and professional staff of the NBA to best enable the NBA to provide strong leadership, management and support to maintain Australia’s world-class blood supply and continue to save and improve the lives of all Australians who depend on these precious products.
Deputy Chief Executives
Michael Stone has been a Deputy Chief Executive at the National Blood Authority (NBA) since 2010 and has been with the NBA since its establishment in 2003.
He is responsible for commercial strategy, tendering and contracting for national supply of immunoglobulin, albumin, clotting factor concentrate, and other plasma derived products, recombinant and other alternative products, and diagnostic reagent products. This includes national supply planning processes, and the coordination of the assessment of proposals for public funding of new products.
In this role Michael is responsible for the national Immunoglobulin Governance Program, including policy implementation, improved criteria for access, and the online access and authorisation system BloodSTAR, together with associated knowledge development and performance improvement activities. He is also responsible for national blood sector research and development strategic priorities, and a program providing limited funding for research projects in identified key priority areas.
Michael oversees NBA business services areas that include finance and human resources, as well as being the NBA General Counsel and has advised on corporate governance and all major blood supply tendering and contracting processes conducted by the NBA.
His background includes substantial legal experience with the Australian Government Solicitor and the former Australian Government Department of Health and Ageing, and he worked on the establishment of the National Blood Agreement and the NBA. Michael has qualifications in law and economics from the Australian National University.
Elizabeth Quinn joined the National Blood Authority (NBA) in October 2018 as Deputy Chief Executive, Fresh Blood Products and Business Systems. She transferred to the NBA from the Attorney-General’s Department and has a solid background of policy, program and operational management experience.
At the NBA, Elizabeth’s responsibilities encompass fresh blood products and services and related issues, including the coordination of national supply planning processes across Australia. She has principal NBA executive responsibility for the contract with the Australian Red Cross Blood Service. She also has executive responsibility for the CIO group and the NBA’s ICT and data management activities, as well as the coordination of the NBA’s corporate risk management work.
Elizabeth has a background in policy development and service delivery across a range of areas of government including emergency management, legal assistance and international engagement. Elizabeth also served a term as Deputy Commissioner for the Department of Veterans’ Affairs. She first joined the Australian Public Service in 1995.
Elizabeth has a Bachelor of Business (Business Management) from the Royal Melbourne Institute of Technology.
As a small independent agency, the NBA provides an environment that empowers staff to take direct responsibility for delivering significant outcomes in a challenging and ever changing industry. We espouse to foster an environment of diversity, enthusiasm and leadership, with a strong work ethic.
- NBA Organisation Chart (pdf) (125.52 KB)
NBA is also supported by an advisory board. Visit NBA Board for more information.
The NBA activities are guided by three key planning documents that are endorsed by Governments:
- NBA Statement of Expectations and Intent
- Jurisdictional Blood Committee Strategic Plan
- NBA Corporate Plan 2019-20 to 2022-23 (pdf) (4.63 MB)
- NBA Corporate Plan 2019-20 to 2022-23 (docx) (3.61 MB)
- NBA Corporate Plan 2018-19 to 2021-22 (pdf) (4 MB)
- NBA Corporate Plan 2018-19 to 2021-22 (docx) (8.77 MB)
- NBA Corporate Plan 2017-18 to 2020-21 (pdf) (4.14 MB)
- NBA Corporate Plan 2017-18 to 2020-21 (docx) (2.85 MB)
The NBA delivers its required planning outcomes in accordance with a range of more detailed strategies that address specific areas of activities endorsed by governments:
- National Blood Data and Information Strategy 2013-16
- National Wastage Reduction Strategy 2013-17
- National Patient Blood Guidelines Implementation Strategy 2013-17
- National Blood Sector Education and Training Strategy 2013-16
- National Blood Research and Development Statement of Strategic Priorities
- Annual Report for 2018-2019
- Annual Report for 2017-2018
- Annual Report for 2016-2017
- Annual Report for 2015-2016
- Annual Report for 2014-2015
- Annual Report for 2013-2014
- Annual Report for 2012-2013
- Annual Report for 2011-2012
- Annual Report for 2010-2011
- Errata to Annual Report for 2010-2011 (105.7 KB)
- Annual Report for 2009-2010
- Annual Report for 2008-2009
- Annual Report for 2007-2008
- Annual Report for 2006-2007
- Annual Report for 2005-2006 (18 MB)
- Annual Report for 2004-2005 (7.66 MB)
- Annual Report for 2003-2004 (8.53 MB)